Efficacy and Safety of the Dual Glucagon‐Like Peptide‐1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta‐Analysis
Authors' conclusion
Mazdutide was associated with dose-dependent reductions in body weight and HbA1c, with broader metabolic benefits in predominantly Chinese adults with obesity and/or T2D.
Study context
- Population
- Adults with overweight/obesity and/or T2D; Randomized controlled trials (RCTs) identified through PubMed, Scopus, Web of Science and ClinicalTrials.gov to 20 February 2026
- Participants
- 2,292 adults9 RCTs
- Comparison
- Mazdutide vs placebo or active comparators
- Outcome
- Co-primary: percent change in body weight and change in HbA1c
Methodological detailsrandom-effects models, GRADE certainty assessment
- Random-effects models
- GRADE certainty assessment
Pooled result
As reported in the abstract
Percent change in body weight, overweight/obesity without diabetes
MD
−6.56 %
Mazdutide 3 mg
MD
−9.92 %
Mazdutide 4 mg
MD
−11.1 %
Mazdutide 6 mg
Further pooled results
Other metabolic outcomes
- Mazdutide also improved waist circumference, lipids, liver enzymes and uric acid levels
Safety
- Gastrointestinal adverse events were more frequent with mazdutide
- Serious adverse events and treatment discontinuation rates were comparable with comparators
Original publication
Efficacy and Safety of the Dual Glucagon‐Like Peptide‐1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta‐Analysis. Diabetes Obes Metab. Published 6 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →